BICO Group AB (publ) 最近的每股收益为 $-0.84,超出预期 $-0.13 的预期。
BICO Group AB (publ) BCCOY 上一季度的收入表现如何?
BICO Group AB (publ) 上一季度的收入为 $-0.84
BICO Group AB (publ) 的收入预期是多少?
根据 6 位华尔街分析师的预测,BICO Group AB (publ) 的收入预期范围从 $375.9M 到 $290.08M
BICO Group AB (publ) 的盈利质量评分是多少?
BICO Group AB (publ) 的盈利质量评分为 /。该评分基于盈利能力、增长、现金生成与资本分配以及杠杆四个维度。
BICO Group AB (publ) 何时发布财报?
BICO Group AB (publ) 的下一份财报预计在 2026-05-19 发布
BICO Group AB (publ) 的预期收益是多少?
根据华尔街分析师的预测,BICO Group AB (publ) 的预期收益为 $486.82M
BICO Group AB (publ) 是否超出收益预期?
BICO Group AB (publ) 最近的收益为 $451.3M,未达预期 预期。
关键数据
前收盘价
$0.375
开盘价
$0.65
当日区间
$0.375 - $0.65
52周范围
$0.375 - $0.9
交易量
6.0K
平均成交量
469
股息收益率
--
每股收益(TTM)
-0.60
市值
$103.6M
什么是 BICO GROUP AB?
BICO Group AB engages in the provision of technologies, products, and services to create, understand, and master biology. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 586 full-time employees. The company went IPO on 2016-11-03. The firm focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The firm develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.